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Abstract
Up to now, the ability of target cells to activate protein kinase C (PKC) and protein kinase D 
(PKD) (which is often a downstream target of PKC) has not been examined in natural killer (NK) 
lymphocytes. Here we examined whether exposure of human NK cells to lysis sensitive tumor 
cells activated PKC and PKD. The results of these studies show for the first time that activation of 
PKC and PKD occurs in response to target cell binding to NK cells. Exposure of NK cells to K562 
tumor cells for 10 and 30 minutes increased phosphorylation/activation of both PKC and PKD by 
roughly 2 fold. Butyltins (tributyltin (TBT); dibutyltin (DBT)) and brominated compounds 
(tetrabromobisphenol A (TBBPA)) are environmental contaminants that are found in human 
blood. Exposures of NK cells to TBT, DBT or TBBPA decrease NK cell lytic function in part by 
activating the mitogen activated protein kinases (MAPKs) that are part of the NK lytic pathway. 
We established that PKC and PKD are part of the lytic pathway upstream of MAPKs and thus we 
investigated whether DBT, TBT, and TBBPA exposures activated PKC and PKD. TBT activated 
PKC by 2–3 fold at 10 min at concentrations ranging from 50–300 nM while DBT caused a 1.3 
fold activation at 2.5 μM at 10 min. Both TBT and DBT caused an approximately 2 fold increase 
in phosphorylation/activation of PKC. Exposures to TBBPA caused no statistically significant 
changes in either PKC or PKD activation.
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INTRODUCTION
Natural killer (NK) cells are a part of the innate immune system and lyse tumor, virally 
infected, and antibody-coated cells without prior sensitization (Moretta et al., 2002). NK 
cells are found in the bone marrow, spleen, liver, and peripheral blood and account for 
approximately 10 – 20% of lymphocytes in peripheral blood (Cooper et al 2001; Wu and 
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Lanier, 2003; Lanier, 2005; Moretta et al., 2002; Vivier et al., 2004;). NK cells can stop the 
spread of both metastases and primary tumors (Hanna, 1980; Kiessling and Haller, 1978) 
and individuals who lack NK cells have an increased risk of developing viral infections and 
tumors (Biron et al, 1989; Fleisher et al, 1982; Purdy and Campbell, 2009).
The Protein kinase C (PKC) family of serine/threonine kinases plays an important role in 
signal transduction and the regulation of various cellular functions (Nishizuka 1995; Rosse 
et al., 2010). The binding of tumor cells to NK cells stimulates protein-tyrosine kinase(s) 
(PTK) which activate phospholipase Cγ (PLCγ) leading to production of diacylglycerol 
(DAG) and inositol trisphosphate (IP3) (Steele and Brahmi, 1988a; Ting et al., 1992; 
Whalen et al., 1993) known activators of PKC (Nishizuka 1992). PKC inhibitor and 
activator studies indicated that protein kinase C was part of the lytic signaling pathway 
(Graves et al., 1986; Procopio et al., 1989; Steele and Brahmi, 1988b). Activated PKC 
stimulates Ras which in turn activates Raf-1 the mitogen activated protein kinase (MAPK) 
kinase kinase (MAP3K) component of the lytic pathway (Pearson et al., 2001; Trotta et al., 
1998). Additionally, PKC may also directly activate Raf-1, leading to MAPK activation 
(Ueffing et al., 1997; Xuan et al., 2005).
Protein kinase Ds (PKD)s are another family of serine/threonine kinases that regulate a 
variety of cellular processes, including trafficking, survival, migration, differentiation, and 
proliferation (Kunkel et al., 2007; Johannessen et al., 2007; Newton 1995; Rey et al., 2001; 
Rozengurt et al, 2005). PKD activation occurs by phosphorylation of Serine residues 744 
and 748 found on its catalytic domain by PKC (Rozengurt et al., 2005). PKD activation can 
also be independent of PKC (Lemonnier et al, 2004). Activated PKD can activate MAPKs 
such as p44/42 (Hauser et al., 2001; Wong and Jin 2005) and cAMP-response element 
binding protein (CREB) (Johannessen et al., 2007).
Butyltins (BTs) are found in household, industrial, and agricultural products (Yamada et al., 
1993). Tributyltin (TBT) has been used in wood preservation and marine antifouling paints 
(Kotake, 2012; Roper, 1992; Yamada et al., 1993). It is found in shower curtains, silicon 
baking parchments (Yamada et al., 1993), fish (Kannan et al., 1995) and drinking water 
(Sidiki et al., 1996) leading to human blood levels (as high as 260 nM) (Kannan et al., 1999; 
Loganathan et al., 2000; Whalen et al., 1999). TBT-exposed mammals show increased 
incidences of tumors (Wester et al., 1990) and decreased NK cell function (Ghoneum et al., 
1990). Dibutyltin (DBT) has been used as a stabilizer in plastic products (Omae, 1989; 
Roper 1992) and in polyvinyl chloride (PVC) products used to store drinking water and 
other drinks (Forsyth et al., 1992a,b; Sidiki et al., 1996) as well as a deworming agent in 
poultry (Epstein et al., 1991). DBT has been detected in human blood (as high as 0.3 μM) 
(Kannan et al., 1999; Whalen et al., 1999). Thymus atrophy and pancreatitis are 
consequences of DBT exposure in rats (Merkord et al., 1997; Pieters et al., 1994).
Tetrabromobisphenol A (TBBPA), a flame retardant used in plastics, fabrics, and epoxy 
resin circuit boards (De Wit, 2002; HSDB 2001; IPCS/WHO 1995), has been found in 
seafood (IPCS/WHO, 1995) and drinking water (Peterman et al., 2000). A Japanese study 
showed serum levels of TBBPA at an average of 4.5 ng/g lipid (approximately 33.8 pM) 
(Nagayama et al., 2001), while a Norwegian study found serum levels of 0.24 – 0.71 ng/g 
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lipid (approximately 1.8 – 5.3 pM) (Thomsen et al., 2002). TBBPA interferes with thyroid 
hormone (T4) binding to the human thyroid hormone transport protein transthyretin in vitro 
(Meerts et al., 2000; Hamers et al., 2006). Studies of Wistar rats have shown that TBBPA 
decreases the levels of the circulating thyroid hormone thyroxine (T4) while increasing 
triiodothyronine (T3) levels (Van der Ven et al., 2008) and TBBPA given to newborn rats 
caused polycystic kidney lesions (Fukuda et al., 2004).
Previously we have shown that exposures to TBT, DBT, and TBBPA decrease the lytic 
function of NK cells (Dudimah et al., 2007a, b; Kibakaya et al., 2009) with an 
accompanying activation of MAPKs (Aluoch and Whalen., 2005; Aluoch, et al., 2006; Cato 
et al., 2014; Odman-Ghazi et al. 2010). If MAPKs in NK cells are activated by exogenous 
compounds such as TBT, DBT, or TBBPA, then they could not be subsequently activated by 
the appropriate target, since the binding site on these enzymes would not be available to be 
activated. PKC is needed for the TBT-induced activation of MAPKs in that PKC inhibitors 
block phosphorylation of p44/42 in response to TBT in human NK cells (Abraha et al., 
2010).
Direct activation of PKC by the physiological stimulus of target cells has not previously 
been demonstrated and there are to our knowledge no studies looking at target cell 
stimulation of PKD. The aim of the current study was to examine whether lysis-sensitive 
target cells activate PKC and PKD in NK cells and to determine if these kinases are 
activated by exposure of NK cells to the environmental contaminants, TBT, DBT, and 
TBBPA. These compounds were chosen as they represent different chemical classes, which 
have been demonstrated to activate components of the lytic signaling pathway and decrease 
NK lytic function (Dudimah et al., 2007a, b; Kibakaya et al., 2009; Aluoch and Whalen, 
2005; Aluoch, et al., 2006; Cato et al., 2014; Odman-Ghazi et al. 2010). Neither PKC nor 
PKD were activated by TBBPA (Figure 1), however TBT and DBT caused activation of 
both kinases.
MATERIALS AND METHODS
Preparation of Human NK Cells
Peripheral blood (buffy coat) used in this study was from healthy adult volunteer donors 
(Red Cross, Portland, OR and Key Biologic LLC, Memphis, TN). Highly purified NK cells 
were obtained using a rosetting procedure. NK cells were purified by mixing 30–40 mL of 
buffy coat with 0.6 mL of RosetteSep human NK cell enrichment antibody cocktail (Stem 
Cell Technologies, Vancouver, BC, Canada). The mixture was mixed and incubated for 20 
min at room temperature (25 °C). 7 – 9 mL of the mixture was layered onto 4 mL of 
Lymphosep cell separation media (1.077 g/mL; MP-Biomedicals, Santa Ana, CA) and 
centrifuged at 1200g for 30–50 min. The cell layer was removed and washed twice with 
phosphate buffered saline (PBS, pH 7.2) and stored in complete media (RPMI-1640 
supplemented with 10% heat inactivated bovine calf serum (BCS), 2 mM L-glutamine and 
50 U penicillin G with 50 mg streptomycin/mL) at 1 million cells/mL.
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TBT chloride was purchased from Aldrich Chemical Co. (Milwaukee, WI, USA) as a neat 
solution. TBT was suspended in double de-ionized water to give a 1 mM solution. This TBT 
solution was diluted in cell culture media to achieve the final concentrations. The 
concentration of TBT used in treating the cells ranged from 25 to 300 nM, based on previous 
studies (Whalen et al., 1999, 2002). The concentration of TBT used in the experiments is not 
far greater than the highest concentration that was detected in human blood (as high as 260 
nM; Kannan et al., 1999; Whalen et al., 1999).
DBT dichloride was purchased from Aldrich Chemical Co. (Milwaukee, WI, USA) and is a 
solid at room temperature. DBT was dissolved in dimethylsulfoxide (DMSO). This DBT 
solution was diluted in cell culture media to achieve the final concentrations that ranged 
from 0.5 μM to 10 μM, based on previous studies (Whalen et al., 1999).
TBBPA was purchased from Fisher Scientific. TBBPA was dissolved in DMSO (Sigma-
Aldrich, St. Louis, MO, USA) to yield a 100 mM solution. This TBBPA solution was 
diluted in cell culture media to achieve the concentrations used in treating the cells ranged 
from 0.5 μM to 10 μM. The final concentration of DMSO in any of the TBBPA exposures 
did not exceed 0.01%.
Cell Viability
Cell viability was determined by trypan blue exclusion before and after each exposure 
period. Cell numbers and their viability did not vary among experimental conditions. Cell 
viability was greater than 90% for control, TBT, DBT, and TBBPA treated cells.
Cell Lysates
Cell lysates for western blot were prepared from NK cells treated in the following ways: 1) 
NK cells (2 million per condition) were exposed to K562 (human chronic myelogenous 
leukemia) targets at a 12:1 ratio for 10 min, 30 min, and 1 h. Controls for the presence of 
target cells were done by adding the same number of targets after lysis of the NK cells to 
NK cells that had been incubated with media only; 2) NK cells exposed to 25–300 nM TBT 
or control for 10 min, 1 h, and 6 h; 3) NK cells were exposed to 0.5–10 μM DBT or control 
for 10 min, 1 h, and 6 h; 4) NK cells were exposed to 0.5–10 μM TBBPA or control for 10 
min, 1 h, and 6 h. Following these treatments, the cells were centrifuged and washed with 1 
mL of PBS. The cell pellets were then lysed using 500 μL of lysis buffer per 10 million 
cells. The cell lysates were stored frozen at −80° C up to the point when they were run on 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Each experiment 
was repeated a minimum of three times using cells from different donors.
Western Blot
Cell lysates were run on 10% SDS-PAGE and transferred to polyvinylidene difluoride 
(PVDF) membrane. The PVDF was immunoblotted with anti-phospho-PKD, anti-phospho-
PKC, and anti-β-Actin antibodies (Cell Signaling Technologies, Beverly, MA, USA). 
Antibodies were visualized using a chemiluminescent detection system (Fisher, Atlanta GA, 
USA) and a Kodak Image Station or an UVP Imager (Kodak, Rochester, NY, USA; UVP, 
Rana and Whalen Page 4













Upland CA, USA). The density of each protein band was determined by densitometric 
analysis using the Kodak Image Station or UVP Imager analysis software. A given 
experimental setup (as described in cell lysates section) always had its own internal control. 
Thus, differences and changes in protein expression were determined relative to the internal 
control. This provides relative quantitation by evaluating whether a given treatment changed 
expression of phospho-PKD, PKD, or phospho-PKC compared to the untreated cells. β-
Actin levels were determined for each condition to verify that equal amounts of protein were 
loaded. The density of each protein band was normalized to β-Actin to correct for small 
differences in protein loading among the lanes.
Statistical Analysis
Analysis of variance (ANOVA) followed by pair-wise comparison of data was done for all 
western blot analyses. A minimum of three separate determinations were carried out for 
each western blot experiment (n≥3) and statistical significance was noted at P < 0.05.
RESULTS
Activation of PKC and PKD in NK cells stimulated with K562 target cells
NK cells exposed to K562 tumor cells for 10 min showed increased phosphorylation of both 
PKC (1.5 fold, p<0.05) (Figure 2A) and PKD (2.8 fold, p<0.05) (Figure 3A) as compared to 
control. Exposure to K562 cells for 30 min also significantly increased phosphorylation of 
both PKC and PKD (Figures 2A and 3A). However, after 1 h of exposure there was no 
longer any significant increase in the activation of either kinase. Representative western 
blots are shown in Figures 2B and 3B.
TBT exposures and activation of PKC and PKD in NK Cells
There were statistically significant increases in the phosphorylation/activation of PKC of 
approximately 2 to 3 fold, with respect to control, when NK cells were exposed to 300, 200, 
100, and 50 nM TBT for 10 min (Figure 4A; p < 0.05). A representative western blot of the 
10 min exposures to TBT is shown in Figure 4B. Exposure of NK cells to TBT for 1 h or 6 h 
did not result in any statistically significantly increase in the phosphorylation of PKC among 
the treatment conditions (representative blots Figures 4C and 4D). PKD phosphorylation/
activation increased by about two fold when cells were exposed to 300, 200, and 100 nM 
TBT for 10 min (Figure 5A and 5B; p < 0.05), relative to control. Exposures of NK cells to 
TBT for 1 h (Figure 5C) or 6 h (Figure 5D) did not cause statistically significant increases in 
the phosphorylation of PKD. While a 6 h exposure of NK cells to TBT caused no 
statistically significant change in the phosphorylation of PKD, there were increases seen in 
PKD activation/phosphorylation seen in all donors tested. The specific concentration(s) at 
which an increase occurred varied from donor to donor. Thus, when experiments from all 
donors were combined there was no statistically significant increase seen in the activation of 
PKD (Figure 5D).
DBT exposures and activation of PKC and PKD in NK Cells
Phosphorylation of PKC was increased 1.3 fold compared to control in NK cells exposed to 
2.5 μM DBT for 10 min (Figure 6A and 6B; p<0.05). 1 h exposures to 2.5 and 1 μM DBT 
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increased phosphorylation of PKC 1.4 fold with respect to control (Figure 6C and 6D; p < 
0.05). while 6 h exposures caused no significant increases in phospho-PKC (Figure 6E). 
Phosphorylation of PKD was increased approximately 1.4 fold (Figure 7A and 7B; P<0.05) 
with DBT exposure to 5 μM DBT for 10 min. Exposure of NK cells to DBT for 1 h or 6 h 
caused no statistically significant increase in the phospho-PKD (Figures 7C and 7D).
DISCUSSION
The current study investigated whether exposure of NK cells to the physiological stimulus of 
tumor target cells resulted in activation of PKC and PKD. Additionally it addressed whether 
these two important kinases were activated when NK cells were exposed to the 
environmental toxicants, TBT, DBT, and TBBPA. We found that PKC is activated within 10 
minutes of exposing NK cells to target cells, such an activation had not been previously 
demonstrated. Additionally, PKD, a known substrate for certain PKCs, was also activated by 
NK interaction with target cells. These data suggest that activation of PKD, most likely due 
to activation of PKC, is a component of the lytic pathway activated in NK cells by 
interaction with their targets. To our knowledge, activation of NK cell PKD by targets has 
not previously been shown.
Previous studies have shown that butyltin (TBT and DBT) and brominated flame retardant 
(TBBPA) compounds, known to contaminate human tissues (Whalen et al., 1999; Kannan et 
al., 1999; Nagayama et al., 2001; Thomsen et al., 2002) are able to interfere with the lytic 
function of human NK cells (Dudimah et al., 2007a, b; Kibakaya et al., 2009). Further, the 
loss of lytic function appears to be at least in part due to the ability of these compounds to 
activate MAPK activity in the NK cell (Aluoch and Whalen 2005; Aluoch et al., 2006; 
Odman-Ghazi et al., 2010; Cato et al., 2014). The activation of MAPKs by the compounds 
leaves the NK cell unable to activate MAPKs in response to a subsequent encounter with an 
appropriate target cell.
Here we show that both PKC and PKD are activated by the butyltin compounds (BTs) but 
not by the brominated flame retardant, TBBPA. Structurally, BTs and TBBPA differ 
considerably (Figure 8A,B,C). All of these compounds are quite hydrophobic. Octanol-
water partition coefficients (Kow) for TBT range from 5000–7000 (Laughlin et al., 1986) 
while the Kow of DBT is about 10–1300 (Harper, 2005). The differences in hydrophobicity 
between TBT and DBT are quite significant and are due to the loss of the third butyl group. 
TBBPA has a wide range of measured Kow (1584–2,511,866) at neutral pH (ECB, 2006). 
TBBPA has some structural similarity to thyroid hormones and has been shown to compete 
with thyroid hormone binding (T4) to transthyretin (Meerts et al., 2000; Hamers et al., 
2006). TBBPA may also increase serum estrogen levels due to its ability to compete with 
estrogen for the glucuoronyltransferases and sulfotransferases needed for estrogen 
elimination (Lai et al., 2015). BTs have no such structural similarity to T4 (Kotake, 2012). 
However, TBT binds to the retinoid X receptor with high affinity and acts as agonist for this 
nuclear receptor/transcription regulator (le Maire et al., 2009). TBT also increases the 
activity of aromatase (estrogen synthetase) (Nakanishi et al., 2002), while DBT has been 
shown to decrease ligand binding to the glucocorticoid receptor (Gumy et al., 2008). 
Additionally, TBT increases the phosphorylation and total of levels of the c-Jun component 
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of the AP-1 transcription regulator (Person and Whalen, 2010). Thus, each of these 
compounds affects the status of transcriptional regulators. Activation of PKC (and possibly 
PKD) by TBT as demonstrated here may lead to the observed activation of MAPKs (Aluoch 
et al. 2006) resulting in alteration of AP-1 regulated transcription. A number of functions of 
NK cells can be regulated by MAPK controlled transcription regulators such as AP-1 
including synthesis of the cytolytic protein, granzyme (Hanson et al., 1993), and the 
cytokine, interferon gamma (Samten et al., 2008).
The data in the current study indicate that TBT exposure can cause activation of both PKC 
and PKD in human NK cells. It appears that TBT may be activating the MAPK pathway(s) 
by activating PKC and PKD. There is data in other cell types indicating that PKD is part of 
the upstream activation pathway for p44/42 MAPK (Johannessen et al., 2007). The most 
upstream component of the MAPK activation/NK lytic pathway that has previously been 
shown to be activated by TBT is MAP3K (Raf-1) (Celada and Whalen, 2014). The data 
from this study indicate that TBT activation of further upstream components of the pathway, 
PKC and PKD, is occurring with exposure to TBT. As mentioned earlier, the activation of 
MAPKs (especially p44/42) by TBT could lead to loss of lytic function (Dudimah et al. 
2007a), due to the fact that they would no longer be available for activation by a subsequent 
encounter with target cells. As with TBT, exposures to DBT lead to activation of both PKC 
and PKD, even if to a lower extent. Due to its lower hydrophobicity with respect to TBT, 
DBT is probably less capable of penetrating cell membranes, especially because of the 
hydrophobic barrier of the lipid bilayer. It is also possible that DBT interacts with a larger 
array of intracellular targets some of which may have effects that counteract its ability to 
activate PKC and PKD.
TBBPA has also been shown to decrease the lytic function of human NK cells (Kibakaya et 
al., 2009) with accompanying activation of MAPKs (Cato et al., 2014). However, in this 
study we found that the potential upstream activator of the MAPK pathway(s), PKC, was 
not activated when NK cell were exposed to TBBPA. Additionally, PKD was not activated 
when NK cells were exposed to TBBPA. This is in contrast to TBT and DBT, which both 
activate MAPKs and also activated PKC. It is also distinct from the activating effect that 
TBBPA has on PKC in the immune cells (hemocytes) of marine mussels (Canesi et al., 
2005). TBBPA is structurally very distinct from the two butyltins (Figure 8), and clearly 
interacts with a different set of target molecules (Meerts et al., 2000; Hamers et al., 2006; 
Lai et al., 2015) than the BTs (le Maire et al., 2009; Nakanishi et al., 2002; Gumy et al., 
2008). Thus it is not surprising that it appears to utilizes a mechanism for activating the NK 
lytic pathway that does not include PKC and PKD activation.
In summary, the results from this study indicate: 1) Exposure of human NK cells to lysis 
sensitive tumor target cells increases phosphorylation/activation of both PKC and PKD 
within 10 minutes of exposure and this activation maintains for 30 minutes; 2) NK cell 
exposure to the butyltin compounds, TBT and DBT, increase phosphorylation/activation of 
both PKC and PKD; 3) There was no increased phosphorylation/activation of PKC and PKD 
in NK cells exposed to the brominated flame retardant, TBBPA, for 10 min, 1 h, and 6 h. 
The spurious activation by TBT and DBT of PKC and PKC, upstream components of the 
lytic signaling pathway in NKs, is consistent with the described MAPK pathway activation 
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(Aluoch et al. 2006; Odman-Ghazi et al., 2010) and loss of lytic function (Dudimah et al., 
2007a b) caused by BT exposures. However, the demonstrated activation of MAPKs and 
decreases in lytic function caused by TBBPA (Kibakaya et al., 2009; Cato et al., 2014) 
cannot be attributed to the activation of these upstream components of the lytic signaling 
pathway.
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Effects of exposures to TBBPA on the phosphorylation/activation state of PKC and PKD in 
NK cells: Representative experiment for 10 min exposures to TBBPA. Experiment was 
repeated using cells from seven different donors.
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Effects of incubations with K562 target cells on phosphorylation/activation state of PKC in 
NK cells: A) levels of phospho-PKC normalized to the control. B) Representative Western 
blot. Experiments were repeated using cells from five different donors. Asterisks indicate a 
significant difference as compared with control, p<0.05.
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Effects of incubations with K562 target cells on phosphorylation/activation state of PKD in 
NK cells: A) levels of phospho-PKD normalized to the control. B) Representative Western 
blot. Experiments were repeated using cells from five different donors. Asterisks indicate a 
significant difference as compared with control, p<0.05.
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Effects of exposures to TBT on the phosphorylation/activation state of PKC in NK cells: A) 
levels of phospho-PKC normalized to the control for 10 min exposures to TBT. B) 
Representative experiment for 10 min exposures to TBT. C) Representative experiment for 1 
h exposures to TBT. D) Representative experiment for 6 h exposures to TBT. Experiments 
were repeated using cells from five different donors. Asterisks indicate a significant 
difference as compared with control, p<0.05.
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Effects of exposures to TBT on the phosphorylation/activation state of PKD in NK cells: A) 
levels of phospho-PKD normalized to the control for 10 min exposures to TBT. B) 
Representative experiment for 10 min exposures to TBT. C) Representative experiment for 1 
h exposures to TBT. D) Representative experiment for 6 h exposures to TBT. Experiments 
were repeated using cells from five different donors. Asterisks indicate a significant 
difference as compared with control, p<0.05.
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Effects of exposures to DBT on the phosphorylation/activation state of PKC in NK cells: A) 
levels of phospho-PKC normalized to the control for 10 min exposures to DBT B) 
Representative experiment for 10 min exposures to DBT. C) levels of phospho-PKC 
normalized to the control for the 1 h exposures to DBT. D) Representative experiment for 1 
h exposures to DBT. E) Representative experiment for 6 h exposures to DBT. Experiments 
were repeated using cells from six different donors for 10 min and 1h and form three 
different donors for 6 h. Asterisks indicate a significant difference as compared with control, 
p<0.05.
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Effects of exposures to DBT on the phosphorylation/activation state of PKD in NK cells: A) 
levels of phospho-PKD normalized to the control for 10 min exposures to DBT. B) 
Representative experiment for 10 min exposures to DBT. C) Representative experiment for 
1 h exposures to DBT. D) Representative experiment for 6 h exposures to DBT. 
Experiments were repeated using cells from five different donors (10 min), six different 
donors (1 h) and three different donors (6 h). Asterisks indicate a significant difference as 
compared with control, p<0.05.
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Structures of A) Tributytin chloride, B) Dibutytin dichloride, and C) Tetrabromobisphenol 
A.
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